Results 51 to 60 of about 3,972 (148)

The FGF/FGFR System in the Biology and Therapeutic Landscape of Pediatric CNS Tumors

open access: yesMedicinal Research Reviews, EarlyView.
ABSTRACT Central nervous system (CNS) tumors are the most common solid malignancies in children, comprising a highly heterogeneous group of neoplasms defined by distinct molecular alterations and clinical behaviors. Advances in molecular genetics have underscored the relevance of specific signaling pathways in driving pediatric tumorigenesis, among ...
Serena Filiberti   +6 more
wiley   +1 more source

Case report: EML4::NTRK3 gene fusion in a patient with metastatic lung adenocarcinoma successfully treated with entrectinib

open access: yesFrontiers in Oncology, 2022
Rearrangements involving the neurotrophin kinase (NTRK) genes NTRK1, NTRK2 and NTRK3 with different fusion partners have been observed in both adult and pediatric solid tumors.
Chiara Lazzari   +7 more
doaj   +1 more source

Precision medicine in cancer: A comprehensive review of advanced cancer diagnosis technologies and personalized treatment strategies

open access: yesPrecision Medical Sciences, EarlyView.
The translational pipeline of precision medicine in clinical oncology. Schematic overview of the individualized cancer care workflow. (1) Input: Patient samples undergo multi‐omic profiling via NGS, single‐cell diagnostics, spatial maps, and epigenetic sequencing.
Asif Jan   +3 more
wiley   +1 more source

Larotrectinib Has Antitumor Activity in TRK+ Pediatric Solid Tumors

open access: yes, 2018
Larotrectinib achieved a 93% response rate in pediatric patients with TRK fusion–positive tumors.

core   +1 more source

Frequency of Clinically Relevant Drug–Drug Interactions Between Tyrosine Kinase Inhibitors and Proton Pump Inhibitors in Patients With Cancer Using Real‐World Data

open access: yesBasic &Clinical Pharmacology &Toxicology, Volume 139, Issue 5, November 2026.
ABSTRACT Background Proton pump inhibitors (PPIs) raise stomach pH, leading to reduced bioavailability of many tyrosine kinase inhibitors (TKIs), thereby affecting treatment outcomes. To what extent this interaction occurs in clinical practice remains underexplored.
Grietje van Elp   +5 more
wiley   +1 more source

Metastatic SQSTM1-NTRK1 fused non-small-cell lung cancer treated with larotrectinib and stereotactic radiosurgery resulting in durable complete response: a case report

open access: yesTherapeutic Advances in Medical Oncology
Lung cancer is one of the most common malignancies and causes the most cancer deaths in the United States. Targeted therapies have improved the survival of patients with advanced disease. Neurotrophic tropomyosin receptor kinase (NTRK) fusions are a rare
Colton Betts   +2 more
doaj   +1 more source

Next‐Generation Sequencing‐Based Molecular Profiling and Management of Advanced Solid Tumors: A Real‐World Experience in a Community‐Based Academic Cancer Center

open access: yesCancer Medicine, Volume 15, Issue 10, October 2026.
ABSTRACT Background Advances in molecular and cell biology have led to a paradigm shift in cancer management. We implemented next‐generation sequencing (NGS) at our community‐based academic cancer center over a decade ago. We sought to optimize the use of genomics and understand its impact in identifying actionable genomic alterations to determine ...
Gayathri Moorthy   +19 more
wiley   +1 more source

Cancer Cell Metastasis: From Molecular Mechanisms to Therapeutic Strategies

open access: yesMedComm, Volume 7, Issue 10, October 2026.
The schematic representation of intrinsic and extrinsic influences of cancer cell metastasis. Genomic evolution of metastatic tumor cells (MTCs) promotes their metastatic phenotypes and reconstruct the primary tumor microenvironment. During MTCs migration along different routes (blood circulation, lymphatic vessels, and perineuronal spaces), the ...
Yupeng Zhao   +7 more
wiley   +1 more source

From Real World Data to Real Impact: A Co‐Medication Framework for Lung Cancer to Advance DDI Assessment and Patient‐Centric Drug Development

open access: yesClinical and Translational Science, Volume 19, Issue 10, October 2026.
ABSTRACT Lung cancer predominantly affects older adults who already experience comorbidities and are at increased risk of drug–drug interactions (DDIs) due to polypharmacy. Traditional DDI assessments often do not fully capture complex co‐medication patterns observed in real‐world practice due to the risk of introducing confounding factors.
Mareena Biju   +6 more
wiley   +1 more source

More Than a Birthmark? A Growing Pediatric Skin Lesion

open access: yes
JEADV Clinical Practice, EarlyView.
Shatha Ahmad Al Hajjaj   +2 more
wiley   +1 more source

Home - About - Disclaimer - Privacy